-
Study aim
-
The effect of nebulized furosemide on spirometric indexes in Chronic Obstructive Pulmonary Disease exacerbation patients
-
Design
-
A clinical trial with a control group was randomized with parallel, blind, and randomized groups.
-
Settings and conduct
-
This is a randomized clinical trials that was performed in COPD exacerbation patients in the year 1399 to 98 referred to emergency department of Imam Khomeini Hospital in Sari. Patients are randomly divided into two groups.The randomized method is Numbered drug containers. Doctor prescribing medications and patients, and analyst is not aware of the type of prescription drug. Spirometery are performed for two groups before prescribing drugs, 30 minutes and one hour after administration.
-
Participants/Inclusion and exclusion criteria
-
This is a triple-blind randomized clinical trial that was performed in COPD exacerbation patients in the year 1399 to 98 referred to emergency department of Imam Khomeini Hospital in Sari. Inclusion criteria include COPD exacerbation and FEV1/FVC ratio of less than 70% and no need for ventilator. Exclusion criteria include increased FEV1 of more than 200cc or 12% after salbutamol administration in spirometry, history of recent infectious diseases, rheumatoid arthritis, degenerative joint disease, vasculitis, and The probability of malignancy is based on the examination.
-
Intervention groups
-
The case group received 40 mg of furosemide (Chemidarou Industrial Company, Tehran, Iran, 20 mg/2 cc) in a 15-minute period. The control group received 4 ml of normal saline serum of 0.9% as an nebulized in 15 minutes. The Omron NE-C900 is used to produce the incense. For both groups, 5 mg salbutamol is administered as an nebulized for 15 minutes and 125 mg methyl prednisolone.
-
Main outcome variables
-
FEV1, FVC, FEV1 / FVC , PEFR , complications